CSIRO Publishing blank image blank image blank image blank imageBooksblank image blank image blank image blank imageJournalsblank image blank image blank image blank imageAbout Usblank image blank image blank image blank imageShopping Cartblank image blank image blank image You are here: Journals > Sexual Health   
Sexual Health
Journal Banner
  Publishing on sexual health from the widest perspective
 
blank image Search
 
blank image blank image
blank image
 
  Advanced Search
   

Journal Home
About the Journal
Editorial Structure
Contacts
Content
Online Early
Current Issue
Just Accepted
All Issues
Special Issues
Sample Issue
For Authors
General Information
Scope
Submit Article
Author Instructions
Open Access
For Referees
Referee Guidelines
Review an Article
Annual Referee Index
For Advertisers
For Subscribers
Subscription Prices
Customer Service

blue arrow e-Alerts
blank image
Subscribe to our Email Alert or RSS feeds for the latest journal papers.

red arrow Connect with us
blank image
facebook twitter LinkedIn

red arrow Interview with Kit Fairley
blank image
Hear Kit Fairley speak about what is sexual health.

 

Article << Previous     |     Next >>   Contents Vol 11(4)

Attitudes towards microbicide use for bacterial vaginosis in pregnancy

Marina Catallozzi A B E, Camille Y. Williams A, Gregory D. Zimet C, Katharine M. Hargreaves A, Shari E. Gelber D, Adam J. Ratner A, Lawrence R. Stanberry A and Susan L. Rosenthal A

A Department of Pediatrics, Columbia University College of Physicians & Surgeons-Morgan Stanley Children’s Hospital of New York Presbyterian Hospital, 622 West 168th Street, New York, NY 10032, USA.
B Heilbrunn Department of Population & Family Health, Mailman School of Public Health New York, 60 Haven Avenue, New York, NY 10032, USA.
C Department of Pediatrics, Indiana University School of Medicine, 410 West 10th Street, Indianapolis, IN 46202, USA.
D Weill Cornell Medical College, 525 East 168th Street, New York, NY 10065, USA.
E Corresponding author. Email: mc2840@cumc.columbia.edu

Sexual Health 11(4) 305-312 http://dx.doi.org/10.1071/SH14011
Submitted: 10 January 2014  Accepted: 27 May 2014   Published: 21 August 2014


 
PDF (152 KB) $25
 Export Citation
 Print
  
Abstract

Background: Bacterial vaginosis (BV) is the most common reproductive tract infection (RTI) and is a significant risk factor for preterm birth. Microbicides could be an option for the prevention and treatment of BV in pregnancy, and understanding use of the product will be crucial. The present study explored attitudes of women in the third trimester of pregnancy regarding topical microbicide use for the prevention and treatment of BV. Methods: Twenty-six women in their third trimester were interviewed regarding their knowledge and beliefs about RTIs during pregnancy and attitudes concerning the use of topical microbicides for prevention and treatment of BV. Results: Participants had a mean age of 24.9 years, were largely under-represented minorities and the majority had had past pregnancies. Participants had knowledge and experience with RTIs but not BV. They were open to the use of microbicides for prevention or treatment of BV, but believed that women requiring treatment would be more motivated. Rationales for acceptability were most commonly related to the baby’s health. Practical issues that may interfere with use were often, but not always, related to pregnancy. There was a range of attitudes about partner involvement in decision-making and the practicalities of product use. Conclusion: Pregnant women are knowledgeable about RTIs but not necessarily BV. The women in this study found microbicide use acceptable, particularly for treatment. To improve acceptability and use, education would be needed about BV and possible complications, how to overcome practical problems and the value of involving partners in the decision.

Additional keywords: acceptability, prevention, topical microbicides, treatment.


References

[1]  Koumans EH, Sternberg M, Bruce C, McQuillan G, Kendrick J, Sutton M, et al The prevalence of bacterial vaginosis in the United States, 2001–2004; associations with symptoms, sexual behaviors, and reproductive health. Sex Transm Dis 2007; 34: 864–9.
CrossRef | PubMed |

[2]  Brocklehurst P, Gordon A, Heatley E, Milan SJ. Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database Syst Rev 2013; 1: CD000262
| PubMed |

[3]  Allsworth JE, Peipert JF. Prevalence of bacterial vaginosis: 2001–2004 National Health and Nutrition Examination Survey data. Obstet Gynecol 2007; 109: 114–20.
CrossRef | PubMed |

[4]  Ralph SG, Rutherford AJ, Wilson JD. Influence of bacterial vaginosis on conception and miscarriage in the first trimester: cohort study. BMJ 1999; 319: 220–3.
CrossRef | CAS | PubMed |

[5]  Kurki T, Sivonen A, Renkonen OV, Savia E, Ylikorkala O. Bacterial vaginosis in early pregnancy and pregnancy outcome. Obstet Gynecol 1992; 80: 173–7.
| CAS | PubMed |

[6]  Riduan JM, Hillier SL, Utomo B, Wiknjosastro G, Linnan M, Kandun N. Bacterial vaginosis and prematurity in Indonesia: association in early and late pregnancy. Am J Obstet Gynecol 1993; 169: 175–8.
CrossRef | CAS | PubMed |

[7]  McGregor JA, French JI, Parker R, Draper D, Patterson E, Jones W, et al Prevention of premature birth by screening and treatment for common genital tract infections:results of a prospective controlled evaluation. Am J Obstet Gynecol 1995; 173: 157–67.
CrossRef | CAS | PubMed |

[8]  Hillier SL, Nugent RP, Eschenbach DA, Krohn MA, Gibbs RS, Martin DH, et al The Vaginal Infections and Prematurity Study Group. Association between bacterial vaginosis and preterm delivery of a low-birth-weight infant. N Engl J Med 1995; 333: 1737–42.
CrossRef | CAS | PubMed |

[9]  Brotman RM, Klebanoff MA, Nansel TR, Yu KF, Andrews WW, Zhang JA, et al Bacterial vaginosis assessed by gram stain and diminished colonization resistance to incident gonococcal, chlamydial, and trichomonal genital infection. J Infect Dis 2010; 202: 1907–15.
CrossRef | PubMed |

[10]  Taha TE, Hoover DR, Dallabetta GA, Kumwenda N, Mtimavlye LAR, Yang L-P, et al Bacterial vaginosis and disturbances of vaginal flora: association with increased acquisition of HIV. AIDS 1998; 12: 1699–706.
CrossRef | CAS | PubMed |

[11]  Denney JM, Culhane JF. Bacterial vaginosis: a problematic infection from both a perinatal and neonatal perspective. Semin Fetal Neonatal Med 2009; 14: 200–3.
CrossRef | PubMed |

[12]  O’Toole G, Kaplan HB, Kolter R. Biofilm formation as microbial development. Annu Rev Microbiol 2000; 54: 49–79.
CrossRef | CAS | PubMed |

[13]  Swidsinski A, Mendling W, Loening-Baucke V, Ladhoff A, Swidsinki S, Hale L, et al Adherent biofilms in bacterial vaginosis. Obstet Gynecol 2005; 106: 1013–23.
CrossRef | PubMed |

[14]  Swindinski A, Mendling W, Loening-Baucke V, Dörffel Y, Scholze J, Verstraelen H. An adherent Gardnerella vaginalis biofilm persists on the vaginal epithelium after standard therapy with oral metronidazole. Am J Obstet Gynecol 2008; 198: e1–6.

[15]  Harwell JI, Moench T, Mayer KH, Chapman S, Rodriguez I, Cu-Uvin S. A pilot study of treatment of bacterial vaginosis with a buffering vaginal microbicide. J Womens Health (Larchmt) 2003; 12: 255–9.
CrossRef |

[16]  Hymes SR, Randis TM, Sun TY, Ratner AJ. DNase inhibits Gardnerella vaginalis biofilms in vitro and in vivo. J Infect Dis 2013; 207: 1491–7.
CrossRef | CAS | PubMed |

[17]  Tolley EE, Severy LJ. Integrating behavioral and social science research into microbicide clinical trials: challenges and opportunities. Am J Public Health 2006; 96: 79–83.
CrossRef | PubMed |

[18]  Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329: 1168–74.
CrossRef | CAS | PubMed |

[19]  Skoler-Karpoff S, Ramjee G, Ahmed K, Altini L, Plagianos MG, Friedland B, et al Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 1977–87.
CrossRef | CAS | PubMed |

[20]  Marrazzo J, Ramjee G, Nair G, Palanee T, Mkhize B, Nakabiito C, et al. Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtricitabine or vaginal tenofovir gel in the VOICE Study (MTN 003). In Proceedings of the 20th Conference on Retroviruses and Opportunistic Infections; March 2013; Atlanta, GA. Abstract 26LB. Available online at: http://www.hivsharespace.net/node/2942 [verified 21 July 2014].

[21]  Chacko MR, Anding R, Kozinetz CA, Grover JL, Smith PB. Neural tube defects: knowledge and preconceptional prevention practices in minority young women. Pediatrics 2003; 112: 536–42.
CrossRef | PubMed |

[22]  Hurley KM, Caulfield LE, Sacco LM, Costigan KA, Dipietro JA. Psychosocial influences in dietary patterns during pregnancy. J Am Diet Assoc 2005; 105: 963–6.
CrossRef | PubMed |

[23]  Latva-Pukkila U, Isolauri E, Laitinen K. Dietary and clinical impacts of nausea and vomiting during pregnancy. J Hum Nutr Diet 2010; 23: 69–77.
CrossRef | CAS | PubMed |

[24]  Thornton PL, Kieffer EC, Salabarría-Peña Y, Odoms-Young A, Willis SK, Kim H, et al Weight, diet, and physical activity-related beliefs and practices among pregnant and postpartum Latino women: the role of social support. Matern Child Health J 2006; 10: 95–104.
CrossRef | PubMed |

[25]  Ritchie J, Spencer L. Qualitative data analysis for applied policy research. In Bryman A, Burgess RG, editors. Analyzing qualitative data. London: Routledge; 1994. pp. 173–94.

[26]  Srivastava A, Thomson SB. Framework analysis: a qualitative methodology for applied policy research. JOAAG 2009; 4: 72–9.

[27]  Giguere R, Carballo-Dieguez A, Ventuneac A, Mabragaña M, Dolezal C, Chen BA, et al Variations in microbicide gel acceptability among young women in the USA and Puerto Rico. Cult Health Sex 2012; 14: 151–66.
CrossRef | PubMed |

[28]  Hammett TM, Norton GD, Mason TH, Langenbahn S, Mayer KH, Robels RR, et al Drug-involved women as potential users of vaginal microbicides for HIV and STD prevention: a three-city survey. J Womens Health Gend Based Med 2000; 9: 1071–80.
CrossRef | CAS | PubMed |

[29]  Moon MW, Khumalo-Sakutukwa GN, Heiman JE, Mbizvo MT, Padian NS. Vaginal microbicides for HIV/STI prevention in Zimbabwe: what key informants say. J Transcult Nurs 2002; 13: 19–23.
CrossRef | PubMed |

[30]  Zubowicz EA, Oakes JK, Short MB, Perfect MM, Succop PS, Rosenthal SL. Adolescents’ descriptions of the physical characteristics of microbicide surrogates and experiences of use. J Womens Health (Larchmt) 2006; 15: 952–61.
CrossRef |

[31]  Coly A, Gorbach PM. Microbicide acceptability research: recent findings and evolution across phases of product development. Curr Opin HIV AIDS 2008; 3: 581–6.
CrossRef | PubMed |

[32]  Friend DR, Kiser PF. Assessment of topical microbicides to prevent HIV-1 transmission: concepts, testing, lessons learned. Antiviral Res 2013; 99: 391–400.
CrossRef | CAS | PubMed |

[33]  Tanner AE, Katzenstein JM, Zimet GD, Cox DS, Cox AD, Fortenberry JD. Vaginal microbicide preferences among midwestern urban adolescent women. J Adolesc Health 2008; 43: 349–56.
CrossRef | PubMed |

[34]  Morrow KM, Fava JL, Rosen RK, Christensen AL, Vargas S, Barroso C. Willingness to use microbicides varies by race/ethnicity, experience with prevention products, and partner type. Health Psychol 2007; 26: 777–86.
CrossRef | PubMed |

[35]  Mantell JE, Myer L, Carballo-Diéguez A, Stein Z, Ramjee G, Morar NS, et al Microbicide acceptability research: current approaches and future directions. Soc Sci Med 2005; 60: 319–30.
CrossRef | PubMed |

[36]  Auslander BA, Perfect MM, Breitkopf DM, Succop PA, Rosenthal SL. Microbicides: information, beliefs, and preferences for insertion. J Womens Health (Larchmt) 2007; 16: 1458–67.
CrossRef |

[37]  Nachega JB, Uthman OA, Anderson J, Peltzer K, Wampold S, Cotton MF, et al Adherence to antiretroviral therapy during and after pregnancy in low-income, middle-income, and high-income countries: a systematic review and meta-analysis. AIDS 2012; 26: 2039–52.
CrossRef | PubMed |

[38]  Roberts CL, Rickard K, Kotsiou G, Morris JM. Treatment of asymptomatic vaginal candidiasis in pregnancy to prevent reterm birth: an open label pilot randomized controlled trial. BMC Pregnancy Childbirth 2011; 11: 18
CrossRef | PubMed |

[39]  Young GL, Jewell D. Topical treatment for vaginal candidiasis (thrush) in pregnancy. Cochrane Database Syst Rev 2001; 4: CD000225
| PubMed |

[40]  Marlow N, Wolke D, Bracewell MA, Samara M. Neurologic and developmental disability at six years of age after extremely preterm birth. N Engl J Med 2005; 352: 9–19.
CrossRef | CAS | PubMed |

[41]  Moster D, Lie RT, Markestad T. Long-term medical and social consequences of preterm birth. N Engl J Med 2008; 359: 262–73.
CrossRef | CAS | PubMed |

[42]  Noble KG, Fifer WP, Rauh VA, Nomura Y, Andrews HF. Academic achievement varies with gestational age among children born at term. Pediatrics 2012; 130: e257–64.
CrossRef | PubMed |

[43]  Carballo-Diéguez A, Giguere R, Dolezal C, Chen BA, Kahn J, Zimet G, et al “Tell Juliana”: acceptability of the candidate microbicide VivaGel(R) and two placebo gels among ethnically diverse, sexually active young women participating in a phase 1 microbicide study. AIDS Behav 2012; 16: 1761–74.
CrossRef | PubMed |

[44]  Severy LJ, Tolley E, Woodsong C, Guest G. A framework for examining the sustained acceptability of microbicides. AIDS Behav 2005; 9: 121–31.
CrossRef | PubMed |

[45]  Braunstein S, van de Wijgert J. Preferences and practices related to vaginal lubrication: implications for microbicide acceptability and clinical testing. J Womens Health (Larchmt) 2005; 14: 424–33.
CrossRef |

[46]  Holmes WR, Maher L, Rosenthal SL. Attitudes of men in an Australian male tolerance study towards microbicide use. Sex Health 2008; 5: 273–8.
CrossRef | PubMed |


   
Subscriber Login
Username:
Password:  

 
    
Legal & Privacy | Contact Us | Help

CSIRO

© CSIRO 1996-2015